{
    "clinical_study": {
        "@rank": "168206", 
        "arm_group": {
            "arm_group_label": "ASP015K + rosuvastatin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study will be to assess the effect of multiple-doses of ASP015K on the\n      pharmacokinetics of rosuvastatin in healthy adult male and female subjects."
        }, 
        "brief_title": "Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics of ASP015K"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must\n             weigh at least 50 kg at screening.\n\n          -  Asian subject must be first generation Japanese born in Japan with both parents and\n             four grandparents of Japanese descent and have resided outside of Japan for 5 years\n             or less, or first generation Chinese born in China with both parents and four\n             grandparents of Chinese descent and have resided outside of China for 5 years or\n             less, or first generation Korean born in Korea with both parents and four\n             grandparents of Korean descent and have resided outside of Korea for 5 years or less.\n\n          -  Non-Asian subject is self-reported as White, Black or African American, and Hispanic\n             or Latino.\n\n          -  Female subject must be of non-childbearing potential (i.e., post-menopausal [defined\n             as at least 1 year without menses] prior to screening or documented surgically\n             sterile or status post hysterectomy [at least 1 month prior to screening]).\n\n          -  Female subject must have a negative pregnancy test at screening and day -1.\n\n          -  Female subject must not donate ova starting at screening and throughout the study\n             period, and for 90 days after the final study drug administration.\n\n          -  Male subject and his female spouse/partner who is of childbearing potential must be\n             using highly effective contraception consisting of two forms of birth control (one of\n             which must be a barrier method) starting at screening and continue throughout the\n             study period and for 90 days after final study drug administration.\n\n          -  Male subject must not donate sperm from screening and throughout the study period and\n             for 90 days after final study drug administration.\n\n          -  Subject agrees not to participate in another investigational study while on\n             treatment.\n\n          -  Subject must be capable of swallowing multiple tablets.\n\n        Exclusion Criteria:\n\n          -  Female subject who has been pregnant within 6 months before screening assessment or\n             breast feeding within 3 months before screening.\n\n          -  Subject has a known or suspected hypersensitivity to rosuvastatin, ASP015K, or any\n             components of the formulations used.\n\n          -  Subject has had a previous intolerance or adverse reaction to a statin therapy.\n\n          -  Subject has any clinically significant history of allergic conditions (including drug\n             allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated,\n             asymptomatic, seasonal allergies at time of dosing).\n\n          -  Subject has any history or evidence of any clinically significant cardiovascular,\n             gastro intestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic,\n             urologic, pulmonary neurologic, dermatologic, psychiatric, renal, and/or other major\n             disease or malignancy, as judged by the Investigator or designee.\n\n          -  Subject has/had febrile illness or symptomatic, viral, bacterial (including upper\n             respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to\n             day -1.\n\n          -  Subject has a mean pulse < 40 or > 90 beats per minute (bpm); mean systolic blood\n             pressure (SBP) > 140 mmHg; mean diastolic blood pressure (DBP) > 90 mmHg\n             (measurements taken in triplicate after subject has been resting in sitting position\n             for at least 5 minutes at screening and day -1.\n\n          -  Subject has used any prescribed or non-prescribed drugs (including vitamins, natural\n             and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug\n             administration, with the exception of hormone replacement therapy (HRT) and\n             intermittent acetaminophen (to a maximum of 2 g/day).\n\n          -  Subject has smoked or has used tobacco-containing products and nicotine or nicotine\n             containing products in the past 6 months prior to screening.\n\n          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week\n             within 6 months prior to screening or has a history of alcoholism or\n             drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit\n             = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).\n\n          -  Subject has a positive test for alcohol, drugs of abuse, or cotinine at screening or\n             day -1.\n\n          -  Subject has used any inducer of liver metabolism (e.g. barbiturates, rifampin) in the\n             3 months prior to day -1.\n\n          -  Subject has had any significant blood loss, donated one unit (450 mL) of blood or\n             more, or received a transfusion of any blood or blood products within 60 days or\n             donated plasma within 7 days prior to clinic check-in on day -1.\n\n          -  Subject has a positive serology test for hepatitis B surface antigen (HBsAg) (total),\n             anti hepatitis A virus (Ig M), anti-hepatitis C virus, anti-hepatitis B core, or anti\n              HIV type 1 or type 2 at screening.\n\n          -  Subject has participated in any interventional clinical study or has been treated\n             with any investigational drugs within 30 days or 5 half-lives of the drug, whichever\n             is longer, prior to screening.\n\n          -  Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOT\u00ae\n             test at screening.\n\n          -  Subject has received any vaccine within 60 days prior to study drug administration.\n\n          -  Subject has had major gastrointestinal surgery or has a medical condition which may\n             inhibit the absorption and/or metabolism of study drug.\n\n          -  Subject anticipates an inability to abstain from xanthine (e.g., caffeine),\n             grapefruit, Seville blood oranges (including marmalade), star fruit, or any products\n             containing these items from 72 hours prior to day -1 and throughout the duration of\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959399", 
            "org_study_id": "015K-CL-PK26"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASP015K + rosuvastatin", 
                "description": "oral tablet", 
                "intervention_name": "ASP015K", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ASP015K + rosuvastatin", 
                "description": "oral tablet", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ASP015K", 
            "healthy subjects"
        ], 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glendale", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91206"
                }, 
                "name": "PAREXEL - Early Phase Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Single-Sequence Drug Interaction Study to Evaluate the Effect of Multiple-Dose ASP015K on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the curve to the last measurable time", 
                "measure": "Pharmacokinetic (PK) parameter for rosuvastatin: AUClast", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 10"
            }, 
            {
                "description": "Area under the curve to the infinity", 
                "measure": "Pharmacokinetic parameter for rosuvastatin: AUCinf", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 10"
            }, 
            {
                "description": "Maximum Concentration", 
                "measure": "Pharmacokinetic parameter for rosuvastatin: Cmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 10"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Composite of pharmacokinetic parameters for rosuvastatin: time after dosing when Cmax occurs (tmax), apparent-terminal elimination half-life (t1/2), apparent volume of distribution (Vz/F), apparent plasma clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 10"
            }, 
            {
                "measure": "Composite of PK parameters for ASP015K: Area under the curve in the dosing interval (AUCtau), Maximum Concentration (Cmax), time after dosing when Cmax occurs (tmax), apparent volume of distribution (Vz/F), apparent plasma clearance at steady (CLss/F)", 
                "safety_issue": "No", 
                "time_frame": "Days 9 and 10"
            }, 
            {
                "description": "Plasma concentration immediately before the next administration of study drug", 
                "measure": "Pharmacokinetic parameter for ASP015K: Ctrough", 
                "safety_issue": "No", 
                "time_frame": "Days 7-10"
            }, 
            {
                "description": "Plasma concentration immediately before the next administration of study drug", 
                "measure": "Pharmacokinetic parameter for ASP015K metabolites: Ctrough", 
                "safety_issue": "No", 
                "time_frame": "Days 7-10"
            }, 
            {
                "measure": "Composite of pharmacokinetic parameters for ASP015K metabolites: Area under the curve in the dosing interval (AUCtau), Maximum Concentration (Cmax), time after dosing when Cmax occurs (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 9 and 10"
            }, 
            {
                "measure": "Safety assessed adverse events, clinical laboratory evaluations, 12-lead ECG measurements, physical examination and vital sign measurements", 
                "safety_issue": "No", 
                "time_frame": "Day 1-14"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Biotech, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}